ZAI LAB LTD-ADR (ZLAB) Stock News

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday

Mentions: HEES INTC SMCI WSO ...

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

Mentions: NVCR

Why Zai Lab (ZLAB) Stock Is Trading Higher

Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Mentions: VRTX

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Mentions: VRTX

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Zai Lab Announces Participation in Investor Conference in January 2025

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Mentions: NVCR

Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results

The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells.

Why Is DexCom (DXCM) Stock Down 38% Today?

DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance.

Mentions: DXCM BFI WINT

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem

A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock.

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Mentions: ARGX

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces Participation in November and December Investor Conferences

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

Zai Lab Announces Participation in September Investor Conferences

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates

Why Is Zynex (ZYXI) Stock Down 24% Today?

Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024.

Mentions: ZYXI DXCM BFI

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Mentions: ARGX